Company intelligence / Profile preview

Garuda Therapeutics

Cambridge, Massachusetts, United Statesgarudatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Garuda is developing off-the-shelf, durable blood stem cell therapies that are self-renewing, HLA-compatible, and transgene-free. Their first product candidate will be evaluated in HLA-matched patients with bone marrow failure syndrome and beta thalassemia. Their technology has the potential to HLA-match approximately 12% of the global population without the need for a donor, with plans to expand to up to half of the global population.

Therapeutic areas: OncologyMetabolic DisordersImmunologyHematology
Modalities: Hematopoietic stem cell (HSC) therapiescellular therapies
Industry: Biotech

Partnerships

Kyowa Kirin Co., Ltd. (strategic investor)

Beyond the preview

Go deeper on Garuda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Garuda Therapeutics.

Explore the full profile